Twist Bioscience Corporation TWST Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 52.1%+5.4pp | 51.6%+7.0pp | 50.7%+8.1pp | 49.2%+8.7pp | 46.7%+8.4pp | |
| Operating margin | -33.9%+24.0pp | -34.4%+28.8pp | -36.2%+34.4pp | -39.3%+40.3pp | -57.9%+16.7pp | |
| Net margin | -19.8%+35.1pp | -19.6%+40.2pp | -20.6%+46.1pp | -23.5%+51.1pp | -55%+14.3pp | |
| EBITDA margin | -27.9%+22.0pp | -28.1%+26.1pp | -29.6%+30.9pp | -32.3%+36.0pp | -49.9%+12.6pp | |
| Free cash flow margin | -23.2%-4.4pp | -22.1%-1.4pp | -20.1%+2.0pp | -19%+6.4pp | -18.8%+15.6pp | |
| Returns | ||||||
| Return on equity | -18.2%+20.1pp | -16.8%+20.9pp | -16.4%+21.7pp | -17.6%+20.8pp | -38.2%-7.8pp | |
| Return on assets | -12.8%+16.7pp | -12.3%+17.1pp | -12.4%+17.7pp | -13.3%+17.1pp | -29.4%-4.8pp | |
| Return on invested capital | -36.4%+19.1pp | -36%+20.2pp | -38.6%+19.8pp | -40.5%+20.2pp | -55.4%-8.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.1× | 0.6×+0.2× | 0.5×+0.2× | |
| Inventory turnover | 7.2×0.0× | 6.7×0.0× | 7.1×+0.7× | 6.8×+1.3× | 7.2×+2.4× | |
| Liquidity | ||||||
| Current ratio | 2.7×-1.8× | 3.8×-1.2× | 3.6×-1.2× | 3.9×-1.0× | 4.5×-1.0× | |
| Quick ratio | 2.4×-1.8× | 3.4×-1.3× | 3.3×-1.2× | 3.6×-0.9× | 4.2×-0.8× | |
| Cash ratio | 1×-1.8× | 1.9×-1.3× | 2×-1.2× | 2.3×-0.9× | 2.8×-0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Per Share | ||||||
| Book value per share | $7.380.0% | $7.47-3.1% | $7.91-2.9% | $7.82-7.4% | $7.38-23.9% | |
| Valuation | ||||||
| Market capitalization | $2.91B+24.4% | $1.94B-29.7% | $1.7B-35.3% | $2.15B-24.6% | $2.34B+18.7% | |
| Enterprise value | $2.9B+30.4% | $1.9B-27.7% | $1.6B-35.4% | $2.04B-24.3% | $2.22B+22.5% | |
| Price / sales | 7.1×+0.4× | 5×-3.4× | 4.5×-3.9× | 5.9×-3.7× | 6.7×-0.4× | |
| Price / book | 6.4×+1.1× | 4.3×-1.8× | 3.6×-2.0× | 4.5×-1.3× | 5.3×+1.8× | |
| EV / sales | 7.1×+0.7× | 4.9×-3.1× | 4.3×-3.7× | 5.6×-3.5× | 6.4×-0.1× | |
| Free cash flow yield | -3.3%-0.5pp | -4.5%-2.0pp | -4.5%-1.8pp | -3.2%-0.6pp | -2.8%+2.0pp | |
| Earnings yield | -2.8%+5.4pp | -3.9%+3.2pp | -4.6%+3.4pp | -4%+3.8pp | -8.2%+1.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Twist Bioscience Corporation's profit margins?
- Twist Bioscience Corporation (TWST) runs a 52.1% gross margin and a -33.9% operating margin, with a -19.8% net margin.
- Where do Twist Bioscience Corporation's ratios come from?
- Every ratio is computed from Twist Bioscience Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
